+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Gilead Sciences Inc (GILD) - Financial and Strategic SWOT Analysis Review

Gilead Sciences Inc (GILD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It carries out the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, cancer, and human immunodeficiency virus (HIV) infection. It markets its products through commercial teams, third-party distributors and corporate partners. Gilead's commercial teams promote its products through direct field contact with physicians, hospitals, clinics and other healthcare providers. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East, and Africa. Gilead is headquartered in Foster City, California, the US.

Gilead Sciences Inc Key Recent Developments

  • May 07, 2024: Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
  • Apr 15, 2024: Gilead Sciences Join Forces With World Hepatitis Alliance and Experts to Award Us$4 Million all4liver Grant for Viral Hepatitis Elimination by 2030, Including Two Community-Led Initiatives in Asia
  • Mar 28, 2024: Xilio and Gilead partner up for IL-12 therapeutic development
  • Mar 18, 2024: Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Gilead Sciences Inc - Key Facts
  • Gilead Sciences Inc - Key Employees
  • Gilead Sciences Inc - Key Employee Biographies
  • Gilead Sciences Inc - Major Products and Services
  • Gilead Sciences Inc - History
  • Gilead Sciences Inc - Company Statement
  • Gilead Sciences Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Gilead Sciences Inc - Business Description
  • Product Category: HIV Products
  • Overview
  • Performance
  • Product Category: Liver Disease
  • Overview
  • Performance
  • Product Category: Oncology
  • Overview
  • Performance
  • Product Category: Other Products
  • Overview
  • Performance
  • Product Category: Veklury
  • Overview
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Other International
  • Performance
  • Geographical Segment: U.S.
  • Performance
  • R&D Overview
  • Gilead Sciences Inc - Corporate Strategy
  • Gilead Sciences Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Gilead Sciences Inc - Strengths
  • Gilead Sciences Inc - Weaknesses
  • Gilead Sciences Inc - Opportunities
  • Gilead Sciences Inc - Threats
  • Gilead Sciences Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Gilead Sciences Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 07, 2024: Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
  • Apr 15, 2024: Gilead Sciences Join Forces With World Hepatitis Alliance and Experts to Award Us$4 Million all4liver Grant for Viral Hepatitis Elimination by 2030, Including Two Community-Led Initiatives in Asia
  • Mar 28, 2024: Xilio and Gilead partner up for IL-12 therapeutic development
  • Mar 18, 2024: Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant
  • Mar 04, 2024: AbTherx Announces Transition from Early Access to Commercialization of its Bispecific and Full Human Diversity Antibody Discovery Technologies
  • Feb 28, 2024: Gilead Announces Funding Initiative To Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
  • Feb 26, 2024: Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
  • Feb 01, 2024: Ted Love, MD, Joins Gilead Sciences’ Board of Directors
  • Dec 21, 2023: Gilead Sciences to Present at Upcoming Investor Conference
  • Dec 19, 2023: Gilead Supports World Health Organization To Bolster Public Health in Bangladesh
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Gilead Sciences Inc, Key Facts
  • Gilead Sciences Inc, Key Employees
  • Gilead Sciences Inc, Key Employee Biographies
  • Gilead Sciences Inc, Major Products and Services
  • Gilead Sciences Inc, History
  • Gilead Sciences Inc, Other Locations
  • Gilead Sciences Inc, Subsidiaries
  • Gilead Sciences Inc, Joint Venture
  • Gilead Sciences Inc, Key Competitors
  • Gilead Sciences Inc, Ratios based on current share price
  • Gilead Sciences Inc, Annual Ratios
  • Gilead Sciences Inc, Interim Ratios
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Gilead Sciences Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Gilead Sciences Inc, Performance Chart (2019 - 2023)
  • Gilead Sciences Inc, Ratio Charts
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Ocera Therapeutics Inc
  • Bristol-Myers Squibb India
  • Abbott Laboratories
  • Novartis AG
  • Enzon Pharmaceuticals Inc
  • Janssen Therapeutics
  • Intercept Pharmaceuticals Inc
  • Precigen Inc
  • Pfizer Inc
  • Incyte Corp
  • GSK plc
  • Earth Science Tech Inc
  • United Therapeutics Corp
  • Celgene Corp
  • Vividion Therapeutics Inc
  • Kineta Inc
  • Checkpoint Therapeutics Inc
  • Viracta Therapeutics Inc
  • Merck & Co Inc
  • hVIVO Services Ltd